Saturday, October 11, 2025

Game-Changing Solution for Heart Inflammation? | David Elsley – Cardiol Therapeutics

FULL DISCLOSURE: This is sponsored content for Cardiol Therapeutics.

In this interview with David Elsley, President and CEO of Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL), we explore the company’s innovative approach to treating inflammatory heart conditions. Cardiol’s lead product, CardiolRx™, is an oral therapy targeting recurrent pericarditis and acute myocarditis – debilitating heart conditions that currently lack effective treatment options.

Elsley discusses their promising Phase 2 trial results presented at the American Heart Association, showing sustained pain reduction and decreased inflammation markers. He explains how their ultra-high-dose, pharmaceutically manufactured formulation differs from standard CBD products, and outlines key upcoming catalysts including Phase 2/3 trial results expected in early 2025 that could accelerate their path to market under FDA’s orphan drug designation.

READ: Cardiol To Advance CardiolRx To Phase III Trial Following Positive Results


FULL DISCLOSURE: Cardiol Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is long the equity of Cardiol Therapeutics. The author has been compensated to cover Cardiol Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Fortune Bay: The Potential Billion Dollar Project

Japan Gold Enters New Chapter as Barrick Alliance Concludes – John Proust

Barrick Mining’s “Company Defining [Gold] Discovery”

Recommended

First Majestic Posts Record Quarterly Silver Production In Q3

Nord Precious Metals Produces High Grade Silver Concentrate From Tailings

Related News

Cardiol Enters Into Supply Agreement With Shoppers Drug Mart

Cardiol Therapeutics Inc. (TSX: CRDL) has entered into a supplier agreement with Medical Cannabis by...

Wednesday, March 18, 2020, 03:27:03 PM

Cardiol Therapeutics Sees Insider Buying From Leadership Team And Board Members

Cardiol Therapeutics (TSX: CRDL) has seen a series of insider buys made in recent days,...
Friday, December 27, 2024, 09:52:00 AM

Cardiol Therapeutics Releases Positive Topline Results From Phase II Clinical Trial

Cardiol Therapeutics (TSX: CRDL) (NYSE: CRDL) has released topline results from their phase two ARCHER...
Thursday, August 7, 2025, 11:28:24 AM

A Heart Disease Cure For Pericarditis? Phase 3 Trial Advances | David Elsley – Cardiol Therapeutics

Discover the major breakthrough at Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) as CEO David Elsley...
Saturday, April 26, 2025, 11:38:00 AM

The Deep Dive Initiates Coverage on Cardiol Therapeutics

With a heavy focus on cannabinoids, Cardiol Therapeutics (TSX: CRDL) is not your typical cannabis...

Monday, April 29, 2019, 07:15:29 AM